Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F. Oberlin O, et al. Among authors: schmitt c. J Clin Oncol. 2009 Nov 10;27(32):5350-5. doi: 10.1200/JCO.2008.17.5257. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826134
Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study.
Gaspar N, Rey A, Bérard PM, Michon J, Gentet JC, Tabone MD, Roché H, Defachelles AS, Lejars O, Plouvier E, Schmitt C, Bui B, Boutard P, Taque S, Munzer M, Vannier JP, Plantaz D, Entz-Werle N, Oberlin O. Gaspar N, et al. Among authors: schmitt c. Eur J Cancer. 2012 Jun;48(9):1376-85. doi: 10.1016/j.ejca.2012.03.017. Epub 2012 Apr 18. Eur J Cancer. 2012. PMID: 22516209 Clinical Trial.
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O. Minard-Colin V, et al. Among authors: schmitt c. Eur J Cancer. 2012 Oct;48(15):2409-16. doi: 10.1016/j.ejca.2012.04.012. Epub 2012 May 25. Eur J Cancer. 2012. PMID: 22633624 Clinical Trial.
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C; Société Française d'Oncologie Pédiatrique (SFOP). Le Deley MC, et al. Among authors: schmitt c. Eur J Cancer. 2007 Mar;43(4):752-61. doi: 10.1016/j.ejca.2006.10.023. Epub 2007 Jan 30. Eur J Cancer. 2007. PMID: 17267204 Clinical Trial.
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J; Société Française des Cancers de l'Enfant. Oberlin O, et al. Among authors: schmitt c. J Clin Oncol. 2006 Aug 20;24(24):3997-4002. doi: 10.1200/JCO.2006.05.7059. J Clin Oncol. 2006. PMID: 16921053 Clinical Trial.
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugieres L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group. Gaspar N, et al. Among authors: schmitt c. Eur J Cancer. 2018 Jan;88:57-66. doi: 10.1016/j.ejca.2017.09.036. Epub 2017 Nov 28. Eur J Cancer. 2018. PMID: 29190507 Clinical Trial.
Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, Landman-Parker J. Gorde-Grosjean S, et al. Among authors: schmitt c. Br J Haematol. 2012 Sep;158(5):649-56. doi: 10.1111/j.1365-2141.2012.09199.x. Epub 2012 Jul 4. Br J Haematol. 2012. PMID: 22757721 Free article.
A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma.
Marec-Berard P, Dalban C, Gaspar N, Brugieres L, Gentet JC, Lervat C, Corradini N, Castex MP, Schmitt C, Pacquement H, Tabone MD, Brahmi M, Metzger S, Blay JY, Pérol D; OSII Thiotepa study group of the French Society of Pediatric Cancer - La Société Française des Cancers de l’Enfant (SFCE) and the French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks. Marec-Berard P, et al. Among authors: schmitt c. Eur J Cancer. 2020 Jan;125:58-68. doi: 10.1016/j.ejca.2019.11.007. Epub 2019 Dec 12. Eur J Cancer. 2020. PMID: 31838406 Clinical Trial.
2,279 results